 SAN DIEGO, March 10, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced today that four abstracts featuring three of its drug candidates will be presented at the American Association for Cancer Research AACR annual meeting, which will convene virtually from April 10-14. 